Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Central Nervous System Protozoal Infections D020808 3 associated lipids
Communicable Diseases, Emerging D021821 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Moraxellaceae Infections D045828 3 associated lipids
Pyloric Stenosis, Hypertrophic D046248 2 associated lipids
Mucositis D052016 7 associated lipids
Tendinopathy D052256 3 associated lipids
Male Urogenital Diseases D052801 1 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Duran JM and Amsden GW Azithromycin: indications for the future? 2000 Expert Opin Pharmacother pmid:11249533
Amábile-Cuevas CF et al. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. 2001 Clin. Infect. Dis. pmid:11249826
De Diego JI et al. Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. 2001 Int. J. Pediatr. Otorhinolaryngol. pmid:11249979
Sahm DF et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. 2001 Antimicrob. Agents Chemother. pmid:11257013
Baumann U et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. 2001 Jan-Feb Infection pmid:11261763
Lietman T and Fry A Can we eliminate trachoma? 2001 Br J Ophthalmol pmid:11264123
Grand A et al. [Subacute infectious endocarditis due to the agent of cat scratch fever: Bartonella henselae]. 2001 Arch Mal Coeur Vaiss pmid:11265556
Graybill JR and Bocanegra R Treatment alternatives for Mycobacterium kansasii. 2001 J. Antimicrob. Chemother. pmid:11266413
Ferwerda A et al. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. 2001 J. Antimicrob. Chemother. pmid:11266417
Butler T et al. In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. 2001 J. Antimicrob. Chemother. pmid:11266420
Bharat V and Mohanty B Bleeding complication during coumarin therapy due to amiodarone and azithromycin. 2000 J Assoc Physicians India pmid:11273517
Gulati R et al. Comparative bioavailability of two formulations of azithromycin. 2000 J Assoc Physicians India pmid:11273540
Parsad D et al. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. 2001 J. Dermatol. pmid:11280457
Waring AL et al. Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State. 2001 J. Clin. Microbiol. pmid:11283060
Holm SO et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. 2001 Bull. World Health Organ. pmid:11285662
Frick KD et al. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. 2001 Bull. World Health Organ. pmid:11285663
Bailey R and Lietman T The SAFE strategy for the elimination of trachoma by 2020: will it work? 2001 Bull. World Health Organ. pmid:11285668
Sorvillo F et al. Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. 2001 Am J Infect Control pmid:11287873
Treadway G Azithromycin: a new 15-membered macrolide. 2001 Jpn J Antibiot pmid:11296412
Hafner R et al. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. 2001 Antimicrob. Agents Chemother. pmid:11302832
Powell FC What's going on in rosacea? 2000 J Eur Acad Dermatol Venereol pmid:11305376
Elewski BE A novel treatment for acne vulgaris and rosacea. 2000 J Eur Acad Dermatol Venereol pmid:11305392
Lechner A and Bruckner DA Oligella ureolytica in blood culture: contaminant or infection? 2001 Eur. J. Clin. Microbiol. Infect. Dis. pmid:11305472
Jacobson JM et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. 2001 AIDS pmid:11316995
Kays MB and Denys GA In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. 2001 Clin Ther pmid:11318076
Gupta S et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. 2001 Clin Ther pmid:11318079
Zarantonelli L et al. Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in Neisseria gonorrhoeae. 2001 J. Antimicrob. Chemother. pmid:11328778
Skerk V et al. Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline. 2001 J Chemother pmid:11330365
Rodríguez Núñez A et al. [Chemoprophylaxis of meningococcal disease with azithromycin and ciprofloxacin]. 2001 An. Esp. Pediatr. pmid:11333489
Samra Z et al. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. 2001 Diagn. Microbiol. Infect. Dis. pmid:11337185
Stein GE and Schooley S Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae. 2001 Diagn. Microbiol. Infect. Dis. pmid:11337186
Griffith DE et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. 2001 Clin. Infect. Dis. pmid:11340525
Tan JS et al. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila. 2001 Clin. Infect. Dis. pmid:11340527
Westfall DS et al. Inoculation of two genotypes of Hemobartonella felis (California and Ohio variants) to induce infection in cats and the response to treatment with azithromycin. 2001 Am. J. Vet. Res. pmid:11341386
Bowden FJ et al. Azithromycin and pelvic inflammatory disease in the Northern Territory. 2001 Med. J. Aust. pmid:11346115
Akritopoulou-Zanze I and Sowin TJ Solid-phase synthesis of macrolide analogues. 2001 May-Jun J Comb Chem pmid:11350254
Littler WA Clindamycin suspension and endocarditis prophylaxis. 2001 Br Dent J pmid:11352383
Tateda K et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. 2001 Antimicrob. Agents Chemother. pmid:11353657
Dinos GP et al. Insights into the mechanism of azithromycin interaction with an Escherichia coli functional ribosomal complex. 2001 Mol. Pharmacol. pmid:11353804
St Clair EW et al. The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. 2001 Arthritis Rheum. pmid:11357896
Kaplan EL et al. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). 2001 Clin. Infect. Dis. pmid:11360224
Fang X et al. [Inhibitory activity of azithromycin on biofilm synthesis and synergism between azithromycin and fleroxacin on Pseudomonas aeruginosa in biofilms]. 1998 Zhonghua Jie He He Hu Xi Za Zhi pmid:11360505
Clearance to market azithromycin as prevention for a common OI in advanced AIDS. 1996 AIDS Patient Care STDS pmid:11361535
Prophylactic antibiotic receives speedy FDA approval to reduce MAC disease in advanced HIV. 1996 AIDS Patient Care STDS pmid:11361569
Azithromycin and OIs. 1996 AIDS Patient Care STDS pmid:11361699
Benson C Advances in the diagnosis and treatment of Mycobacterium avium complex (MAC) disease. 1994 AIDS Patient Care pmid:11362136
What's in the water? 1995 Mar-Apr Treat Rev pmid:11362299
Rifabutin for MAC questioned. 1995 Jul-Aug Posit Aware pmid:11362571
Cheng B Advances in prevention and treatment of MAC. 1995 PI Perspect pmid:11363104
Prescott LM Macrolides, azalides, and streptogrammins. 1996 J Int Assoc Physicians AIDS Care pmid:11363516